• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    7/3/23 9:12:24 AM ET
    $ALVO
    $BACK
    $BXRX
    $CMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ALVO alert in real time by email

    Gainers

    • SQZ Biotechnologies (NYSE:SQZ) stock moved upwards by 58.5% to $0.43 during Monday's pre-market session. The market value of their outstanding shares is at $12.6 million.
    • IMAC Hldgs (NASDAQ:BACK) stock rose 45.18% to $0.16. The company's market cap stands at $5.2 million.
    • Ra Medical Systems (AMEX:RMED) stock rose 19.56% to $1.1. The company's market cap stands at $5.9 million.
    • Myomo (AMEX:MYO) stock moved upwards by 17.65% to $0.61. The company's market cap stands at $12.7 million.
    • Alvotech (NASDAQ:ALVO) stock increased by 14.98% to $8.9. The company's market cap stands at $2.3 billion.
    • Comera Life Sciences (NASDAQ:CMRA) stock rose 14.17% to $0.56. The market value of their outstanding shares is at $12.4 million.

    Losers

    • Laboratory Corp (NYSE:LH) shares decreased by 12.6% to $210.87 during Monday's pre-market session. The market value of their outstanding shares is at $18.6 billion.
    • Baudax Bio (NASDAQ:BXRX) stock declined by 10.26% to $1.05. The market value of their outstanding shares is at $6.3 million.
    • Lipella Pharmaceuticals (NASDAQ:LIPO) stock declined by 8.88% to $1.95. The market value of their outstanding shares is at $11.2 million.
    • Enochian BioSciences (NASDAQ:ENOB) stock decreased by 8.64% to $0.52. The market value of their outstanding shares is at $32.9 million.
    • Xtant Medical Hldgs (AMEX:XTNT) shares decreased by 8.6% to $0.85. The company's market cap stands at $92.5 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares decreased by 7.7% to $3.72. The company's market cap stands at $6.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVO
    $BACK
    $BXRX
    $CMRA

    CompanyDatePrice TargetRatingAnalyst
    Alvotech
    $ALVO
    12/9/2025$5.00Underweight
    Barclays
    Alvotech
    $ALVO
    11/4/2025$8.00Buy → Hold
    Deutsche Bank
    Alvotech
    $ALVO
    10/14/2025$14.00Equal-Weight → Overweight
    Morgan Stanley
    Alvotech
    $ALVO
    9/23/2025$14.00Hold → Buy
    Deutsche Bank
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    Labcorp Holdings Inc.
    $LH
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    Alvotech
    $ALVO
    2/14/2025$18.00Buy
    UBS
    More analyst ratings

    $ALVO
    $BACK
    $BXRX
    $CMRA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 10:44:05 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    $BACK
    $BXRX
    $CMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Alvotech with a new price target

    Barclays initiated coverage of Alvotech with a rating of Underweight and set a new price target of $5.00

    12/9/25 8:42:22 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Alvotech from Buy to Hold and set a new price target of $8.00

    11/4/25 7:41:39 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Alvotech from Equal-Weight to Overweight and set a new price target of $14.00

    10/14/25 8:33:59 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    $BACK
    $BXRX
    $CMRA
    SEC Filings

    View All

    SEC Form S-8 filed by Myomo Inc.

    S-8 - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:49:09 PM ET
    $MYO
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Myomo Inc.

    10-K - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:16:01 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:10:25 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ALVO
    $BACK
    $BXRX
    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Schechter Adam H sold $2,437,047 worth of shares (8,705 units at $279.96), decreasing direct ownership by 10% to 80,773 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    3/5/26 8:57:09 AM ET
    $LH
    Medical Specialities
    Health Care

    EVP, Corporate Affairs Van Der Vaart Sandra D sold $156,000 worth of shares (548 units at $284.91), decreasing direct ownership by 18% to 2,579 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    3/3/26 10:41:42 AM ET
    $LH
    Medical Specialities
    Health Care

    EVP, Pres of ED, CMO & CSO Caveney Brian J sold $429,458 worth of shares (1,500 units at $286.31), decreasing direct ownership by 5% to 30,107 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/26/26 8:25:40 AM ET
    $LH
    Medical Specialities
    Health Care

    $ALVO
    $BACK
    $BXRX
    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $5,355 worth of shares (7,437 units at $0.72), increasing direct ownership by 2% to 481,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/24/25 4:04:45 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Crowley Thomas Aloysius Jr. bought $3,233 worth of shares (4,385 units at $0.74), increasing direct ownership by 6% to 75,748 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/21/25 7:22:22 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $57,500 worth of shares (50,000 units at $1.15), increasing direct ownership by 12% to 474,420 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    8/26/25 8:10:16 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $ALVO
    $BACK
    $BXRX
    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo and Elevance Health Agree to Contract for Multi-State Network Participation

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become effective on a market-by-market basis through the second quarter of 2026. Once complete, the addition of these 45 million medical members will bring Myomo's total number of covered lives under commercial insurance plans to over 80 million. These a

    3/9/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    $ALVO
    $BACK
    $BXRX
    $CMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Alvotech announces planned CEO succession and leadership transition

     - Róbert Wessman to continue serving as Executive Chairman in full-time capacity - Lisa Graver appointed Chief Executive Officer REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company's inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capac

    1/6/26 7:15:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    $BACK
    $BXRX
    $CMRA
    Financials

    Live finance-specific insights

    View All

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

    REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). To listen to the webcast, register here: Q4 and Full Year 2025 webcast registrationTo participate in the Q&A, register here: Q4 and Full Year 2025 conference call registration Slid

    3/4/26 3:00:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ALVO
    $BACK
    $BXRX
    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:09:22 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:00:15 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alvotech

    SC 13G/A - Alvotech (0001898416) (Subject)

    11/6/24 1:51:59 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care